Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
139,800
Employees139,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
139,800
Employees139,800

JNJ Key Statistics

Market cap
485.91B
Market cap485.91B
Price-Earnings ratio
19.49
Price-Earnings ratio19.49
Dividend yield
2.55%
Dividend yield2.55%
Average volume
8.73M
Average volume8.73M
High today
$203.26
High today$203.26
Low today
$200.99
Low today$200.99
Open price
$202.54
Open price$202.54
Volume
7.78M
Volume7.78M
52 Week high
$207.81
52 Week high$207.81
52 Week low
$140.68
52 Week low$140.68

Stock Snapshot

Johnson & Johnson(JNJ) stock is priced at $201.62, giving the company a market capitalization of 485.91B. It carries a P/E multiple of 19.49 and pays a dividend yield of 2.5%.

On 2025-12-09, Johnson & Johnson(JNJ) stock moved within a range of $200.99 to $203.26. With shares now at $201.62, the stock is trading +0.3% above its intraday low and -0.8% below the session's peak.

Trading volume for Johnson & Johnson(JNJ) stock has reached 7.78M, versus its average volume of 8.73M.

The stock's 52-week range extends from a low of $140.68 to a high of $207.81.

The stock's 52-week range extends from a low of $140.68 to a high of $207.81.

JNJ News

Simply Wall St 8h
Johnson & Johnson: Is the 40% Year-to-Date Rally Just Catch-Up to Fair Value?

Johnson & Johnson (JNJ) keeps grinding higher, and with the stock up roughly 14% over the past 3 months and nearly 40% year to date, investors are asking what i...

Johnson & Johnson: Is the 40% Year-to-Date Rally Just Catch-Up to Fair Value?
24/7 Wall St. 13h
Why 2026 Could Be the Breakout Year for Dividend Growth Investors

Why 2026 Could Be the Breakout Year for Dividend Growth Investors Quick Read Procter & Gamble (PG) has raised dividends for 69 consecutive years with a current...

Why 2026 Could Be the Breakout Year for Dividend Growth Investors
Nasdaq 16h
Can J&J Offset Stelara LOE, MedTech China and Legal Headwinds in 2026?

Johnson & Johnson JNJ faces several challenges, like potential losses from expiring drug patents, ongoing legal battles related to its talc powder and broader m...

Can J&J Offset Stelara LOE, MedTech China and Legal Headwinds in 2026?

Analyst ratings

59%

of 27 ratings
Buy
59.3%
Hold
37%
Sell
3.7%

More JNJ News

TipRanks 2d
Eli Lilly, Pfizer, Johnson secure spots on China’s drug catalog, Bloomberg says

Eli Lilly (LLY), Pfizer (PFE), and Johnson & Johnson (JNJ) have secured spots on China’s drug catalog, with a total of 19 medicines making the list, Amber Tong...

Nasdaq 2d
Guru Fundamental Report for JNJ

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our P/B Growth Investor mod...

Guru Fundamental Report for JNJ
TipRanks 2d
Johnson & Johnson announces updated results from Phase 3 CARTITUDE-4 study

Johnson & Johnson announced updated results from the Phase 3 CARTITUDE-4 study supporting durable treatment-free remissions as early as second line treatment wi...

Nasdaq 3d
Johnson & Johnson Reports Durable Remissions With CARVYKTI In CARTITUDE-4 Study

(RTTNews) - Johnson & Johnson (JNJ) announced updated results from the Phase 3 CARTITUDE-4 study, reinforcing the potential of CARVYKTI (ciltacabtagene autoleuc...

Johnson & Johnson Reports Durable Remissions With CARVYKTI In CARTITUDE-4 Study
TipRanks 3d
Nvidia, Microsoft, Super Micro, J&J, McDonald’s: Insider Moves Unveiled!

Insiders have been trading these 5 stocks: ((NVDA)), ((MSFT)), ((SMCI)), ((JNJ)) and ((MCD)). Here is a breakdown of their recent trades and their value. TipRan...

TipRanks 3d
J&J says Inlexzo delivers 74% disease-free survival at one year

Johnson & Johnson announced that new data from the investigational Cohort 4 of the Phase 2b SunRISe-1 study show treatment with gemcitabine intravesical system...

Simply Wall St 4d
Is It Too Late To Consider Johnson & Johnson After Its 40.6% 2025 Rally?

Wondering if Johnson & Johnson is still attractively priced at today’s level, or if the big gains are already behind it? Let’s unpack what the numbers are reall...

Is It Too Late To Consider Johnson & Johnson After Its 40.6% 2025 Rally?

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.